137 related articles for article (PubMed ID: 37424405)
1. Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer.
Fujita KI; Matsumoto N; Murase R; Takeshima K; Ishida H; Kubota Y
Clin Transl Sci; 2023 Oct; 16(10):1741-1747. PubMed ID: 37424405
[TBL] [Abstract][Full Text] [Related]
2. HLA-B15 association with erythema multiforme.
Duvic M; Reisner EG; Dawson DV; Ciftan E
J Am Acad Dermatol; 1983 Apr; 8(4):493-6. PubMed ID: 6406563
[TBL] [Abstract][Full Text] [Related]
3. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
[TBL] [Abstract][Full Text] [Related]
4. [HLA pattern in patients with post-herpetic erythema exsudativum multiforme].
Simon M; Fuchs C
Z Hautkr; 1990 Mar; 65(3):303-4. PubMed ID: 2339577
[TBL] [Abstract][Full Text] [Related]
5. Associations of HLA class I alleles in Japanese patients with Crohn's disease.
Oryoji D; Hisamatsu T; Tsuchiya K; Umeno J; Ueda S; Yamamoto K; Matsumoto T; Watanabe M; Hibi T; Sasazuki T
Genes Immun; 2015; 16(1):54-6. PubMed ID: 25373727
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
8. KIR genes and HLA class I ligands in a Caucasian Brazilian population with colorectal cancer.
Portela P; Merzoni J; Lindenau JD; Damin DC; Wilson TJ; Roesler R; Schwartsmann G; Jobim LF; Jobim M
Hum Immunol; 2017 Mar; 78(3):263-268. PubMed ID: 28088355
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
10. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
13. Recurrent erythema multiforme: tissue typing in a large series of patients.
Schofield JK; Tatnall FM; Brown J; McCloskey D; Navarrete C; Leigh IM
Br J Dermatol; 1994 Oct; 131(4):532-5. PubMed ID: 7947205
[TBL] [Abstract][Full Text] [Related]
14. Human Leukocyte Antigens-B and -C Loci Associated with Posner-Schlossman Syndrome in a Southern Chinese Population.
Zhao J; Zhu T; Chen W; Fan BJ; He L; Yang B; Deng Z
PLoS One; 2015; 10(7):e0132179. PubMed ID: 26161794
[TBL] [Abstract][Full Text] [Related]
15. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation and hitchhiking between structurally polymorphic Alu insertions and HLA-A, -B, and -C alleles and other retroelements within the MHC class I region.
Kulski JK; Shigenari A; Inoko H
Tissue Antigens; 2011 Nov; 78(5):359-77. PubMed ID: 21988723
[TBL] [Abstract][Full Text] [Related]
17. High-resolution human leukocyte antigen (HLA) haplotypes and linkage disequilibrium of HLA-B and -C and HLA-DRB1 and -DQB1 alleles in a Taiwanese population.
Yang KL; Chen SP; Shyr MH; Lin PY
Hum Immunol; 2009 Apr; 70(4):269-76. PubMed ID: 19480851
[TBL] [Abstract][Full Text] [Related]
18. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Lam KO; Lee KC; Chiu J; Lee VH; Leung R; Choy TS; Yau T
Postgrad Med J; 2017 Jul; 93(1101):395-400. PubMed ID: 27836933
[TBL] [Abstract][Full Text] [Related]
19. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
20. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
De Re V; Caggiari L; De Zorzi M; Talamini R; Racanelli V; D' Andrea M; Buonadonna A; Zagonel V; Cecchin E; Innocenti F; Toffoli G
PLoS One; 2014; 9(1):e84940. PubMed ID: 24497922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
